Skip to main content
Premium Trial:

Request an Annual Quote

Strand Life Sciences to Perform In Silico Research for Elan Pharmaceuticals

NEW YORK, Sept. 29 (GenomeWeb News) - Strand Life Sciences will perform in silico drug discovery research for Elan Pharmaceuticals, the Bangalore-based company said today.

 

As part of the collaboration, Strand will use its predictive modeling for efficacy and ADMET, custom library design, QSAR and pharmacophore modeling, structure-basead drug design, and data and visual mining technologies, as well as provide consulting.

 

Earlier this month, Strand Genomics changed its name to Strand Life Sciences. Elan Pharmaceuticals is a subsidiary of Elan, a neuroscience biotechnology company based in Dublinwith 2000 employees worldwide.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.